Blue Jet Healthcare approves Q1 FY 2026-27 results and reappointments of key leaders and auditors
Blue Jet Healthcare · Pharmaceuticals & Biotechnology
Key highlights
- Q1 FY 2026-27 unaudited standalone revenue ₹2931.13 million, profit after tax ₹782.64 million
- Re-appointed Mr. Akshay Bansarilal Arora as Executive Chairman and Whole Time Director for 5 years starting April 13, 2027
- Re-appointed Mr. Shiven Akshay Arora as Managing Director for 5 years from April 13, 2027; re-appointed KKC & Associates LLP as statutory auditors for 5 years from 58th to 63rd AGM
Why it's rated notable: the year-on-year change is 14% (10% to 20% for adverse news)
Original filing
Announcement under Regulation 30 (LODR)-Change in Directorate
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Blue Jet Healthcare
- Fundraise / allotmentMajor developmentBlue Jet Healthcare Limited announces Q2 and H1 FY2027 unaudited financial results
- Financial resultsMajor developmentBlue Jet Healthcare announces unaudited results for quarter ended September 30, 2026
- Board / shareholder meeting outcomeNotable· Adverse for the businessBlue Jet Healthcare Q1 profit ₹782.64 million; re-appointments await AGM approval
- Fundraise / allotmentNotable· Adverse for the businessBlue Jet Healthcare Limited announces Q1 FY2026-27 results and re-appointments
- Financial resultsNotable· Adverse for the businessBlue Jet Healthcare announces Q1 FY27 results and key leadership/auditor appointments
Other fundraise / allotment filings this fortnight
- Supreme Engineering allots 14,50,00,000 warrants at ₹2.60 on preferential basis
- Bajaj Finance Limited allots 5.74 crore warrants to Bajaj Finserv on 10 Nov 2026
- Bajaj Finance approves preferential issue of 5.74 crore warrants to Bajaj Finserv
- Chaman Metallics Limited announces H1 FY27 financial results and proposed Rights Issue
- Harmony Capital Services receives BSE approval for preferential issue of shares
- Kuber Udyog: open offer corrigendum, allotments of shares and warrants at ₹23.10
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.